Weekly Recap: Sevabertinib FDA approval and BAY 3670549 Ph II trial
Bayer AG (XETR:BAYN) is advancing oncology, cardiology and sustainability: sevabertinib won FDA accelerated first—line approval for HER2—mutant NSCLC after strong Phase 1/2 results, a Phase II GIRK4 inhibitor trial for atrial fibrillation launched, and iodine and NewGold canola scale—up plans aim i…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.